Courtney D Nordeck1, Megan Buresh, Noa Krawczyk, Michael Fingerhood, Deborah Agus. 1. Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD (CDN, MF, DA); Behavioral Health Leadership Institute, Baltimore, MD (CDN, MB, MF, DA); Johns Hopkins School of Medicine, Baltimore, MD (MB, MF); Department of Population Health, New York University Grossman School of Medicine, New York, NY (NK).
Abstract
OBJECTIVES: To examine patient characteristics and outcomes among opioid use disorder patients enrolled in low-threshold buprenorphine treatment during the COVID-19 pandemic. METHODS: This paper describes the adaptation of the Project Connections (PC) program, a low-threshold buprenorphine program in Baltimore, in response to the COVID-19 pandemic. This paper examines patient characteristics and initial outcomes of patients served during a rapid protocol shift to telehealth that allowed buprenorphine initiation without an in-person encounter following a state-mandated stay-at-home order. Patient characteristics were compared to a subsample of patients enrolled in the program before the COVID-19 pandemic. RESULTS: In March 2020, there was a sharp increase in new enrollments to the PC program. A total of 143 patients completed an intake assessment between March and May 2020 and 140 began treatment with buprenorphine/naloxone. Those who completed an intake assessment were primarily male (68.5%), Black (83.2%), had a mean age of 43.2 years (SD = 11.7), and reported a mean of 17.0 years of opioid use (SD = 12.9). The majority of patients were unemployed (72.7%) and reported previous criminal justice involvement (69.2%). Of those who completed an intake assessment, 96.5% returned for a second visit. Among those for whom 30-day retention data was available (n = 113), 63.7% were engaged for 30 days or longer. CONCLUSIONS: The PC program illustrates that offering on-demand, flexible treatment is an opportunity to increase opioid use disorder treatment access, even during a public health emergency that disrupted access to services. Relaxation of buprenorphine telehealth regulations allowed for flexibility in treatment and benefits vulnerable populations.
OBJECTIVES: To examine patient characteristics and outcomes among opioid use disorder patients enrolled in low-threshold buprenorphine treatment during the COVID-19 pandemic. METHODS: This paper describes the adaptation of the Project Connections (PC) program, a low-threshold buprenorphine program in Baltimore, in response to the COVID-19 pandemic. This paper examines patient characteristics and initial outcomes of patients served during a rapid protocol shift to telehealth that allowed buprenorphine initiation without an in-person encounter following a state-mandated stay-at-home order. Patient characteristics were compared to a subsample of patients enrolled in the program before the COVID-19 pandemic. RESULTS: In March 2020, there was a sharp increase in new enrollments to the PC program. A total of 143 patients completed an intake assessment between March and May 2020 and 140 began treatment with buprenorphine/naloxone. Those who completed an intake assessment were primarily male (68.5%), Black (83.2%), had a mean age of 43.2 years (SD = 11.7), and reported a mean of 17.0 years of opioid use (SD = 12.9). The majority of patients were unemployed (72.7%) and reported previous criminal justice involvement (69.2%). Of those who completed an intake assessment, 96.5% returned for a second visit. Among those for whom 30-day retention data was available (n = 113), 63.7% were engaged for 30 days or longer. CONCLUSIONS: The PC program illustrates that offering on-demand, flexible treatment is an opportunity to increase opioid use disorder treatment access, even during a public health emergency that disrupted access to services. Relaxation of buprenorphine telehealth regulations allowed for flexibility in treatment and benefits vulnerable populations.
Authors: Alexandria Macmadu; Sivakumar Batthala; Annice M Correia Gabel; Marti Rosenberg; Rik Ganguly; Jesse L Yedinak; Benjamin D Hallowell; Rachel P Scagos; Elizabeth A Samuels; Magdalena Cerdá; Kimberly Paull; Brandon D L Marshall Journal: JAMA Netw Open Date: 2021-09-01
Authors: Samuel R Friedman; Pedro Mateu-Gelabert; Georgios K Nikolopoulos; Magdalena Cerdá; Diana Rossi; Ashly E Jordan; Tarlise Townsend; Maria R Khan; David C Perlman Journal: Glob Public Health Date: 2021-04-11
Authors: Robert Harris; Amanda Rosecrans; Meredith Zoltick; Catherine Willman; Ronald Saxton; Margaret Cotterell; Joy Bell; Ingrid Blackwell; Kathleen R Page Journal: Drug Alcohol Depend Date: 2021-11-26 Impact factor: 4.492
Authors: Kathleen M Ward; Ayden Scheim; Jonathan Wang; Benjamin Cocchiaro; Katie Singley; Alexis M Roth Journal: Drug Alcohol Depend Rep Date: 2022-04-26